Loading...
Sofosbuvir: A novel treatment option for chronic hepatitis C infection
Hepatitis C currently infects more than 170 million people around the world, leading to significant morbidity and mortality. The current standard of care for HCV infection, including one of the two protease inhibitors, telaprevir or boceprevir, for 12-32 weeks, along with pegylated interferon alfa-2...
Na minha lista:
| Udgivet i: | J Pharmacol Pharmacother |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Medknow Publications & Media Pvt Ltd
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4231565/ https://ncbi.nlm.nih.gov/pubmed/25422576 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0976-500X.142464 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|